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Type 2 diabetes mellitus (T2D) is increasing worldwide at an epidemic rate and is expected to reach 
592 million inflicted individuals by 2035 as compared to 382 million in 2013. Obesity is a major risk 
factor for insulin resistance, defined as an impaired cellular effect of insulin, and this precedes the 
development of T2D. Around 85% of subjects with T2D are overweight or obese. However, the 
obesity-associated insulin resistance is not a direct consequence of an increased fat mass per se but 
rather a reduced ability to recruit new subcutaneous adipose cells following weight gain and the 
associated dysregulated, inflamed and insulin-resistant adipose tissue characterized by enlarged 
adipose cells (hypertrophic obesity).  
 
The adipogenic potential of human pre-adipocytes differs between donors and this is related to cell 
size and maintained activation of WNT-signaling in precursor cells. The canonical WNT pathway 
allows the mesenchymal stem cells to proliferate and prevents them from committing to the adipocyte 
linage. We identified a novel secreted “adipokine” induced by WNT activation, WNT1 inducible 
signaling pathway protein 2 (WISP2). WISP2 is preferentially expressed in mesenchymal precursor 
cells and links hypertrophic obesity with canonical WNT-signaling. We found transcriptional 
activation of WISP-2 in the subcutaneous adipose tissue to be a marker of the obesity-associated 
metabolic complications including degree of insulin resistance, ectopic fat accumulation and 
hypertrophic obesity. Mechanistically, we found canonical WNT signaling/WISP2 to regulate 
adipogenic commitment and differentiation in two different ways; - intracellular WISP2 retains the 
PPARγ transcriptional activator ZFP423 in a cytosolic complex which, when dissociated by BMP4, 
allows nuclear entry of ZFP423, induction of PPARγ and commitment into to the adipose lineage and; 
- as a secreted molecule, WISP2 enhances cell proliferation and inhibits adipocyte differentiation by 
activating canonical WNT signaling and, thereby, inhibiting PPARγ activation.  
 
To investigate the effect of WISP2 in vivo, we generated a transgenic mouse model overexpressing 
WISP2 in the adipose tissue under the aP2-promoter. We found WISP2 to be secreted by the adipose 
tissue and present in serum. The mice had a similar body weight but were characterized by improved 
insulin sensitivity, increased circulating levels of adiponectin and the novel FAHFA lipids and 
increased Glut4 in both adipose tissue and skeletal muscle. They were also characterized by markers 
of increased mesenchymal stem cell growth and development with a markedly expanded BAT, a 
”healthy” hyperplastic subcutaneous adipose tissue and increased lean body mass. Serum from the Tg 
mice also increased the proliferation of both brown adipose precursor cells and the mesenchymal 
stem-like CH3T101/2 cells and this was inhibited by adding specific anti-WISP2 monoclonal 
antibodies to the serum.  
 
Taken together, WISP2 is a novel secreted autocrine/endocrine regulator of mesenchymal stem cell 
growth and proliferation as well as their adipogenic commitment. There is important cross-talk 
between WISP2 and BMP4 in the regulation of adipogenic commitment and differentiation and BMP4 
is also a regulator of WISP2 transcriptional activation. WISP2 is a novel target in hypertrophic obesity 
and the Metabolic Syndrome. 
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